Elevance Health, Inc. $ELV Stock Holdings Lifted by Candriam S.C.A.

Candriam S.C.A. grew its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 49.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 91,310 shares of the company’s stock after acquiring an additional 30,409 shares during the quarter. Candriam S.C.A.’s holdings in Elevance Health were worth $35,633,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Elevance Health in the 2nd quarter valued at $7,344,424,000. Bank of New York Mellon Corp bought a new position in shares of Elevance Health during the 2nd quarter valued at $1,246,349,000. Legal & General Group Plc bought a new position in shares of Elevance Health during the 2nd quarter valued at $688,469,000. Amundi raised its position in Elevance Health by 145.7% in the 1st quarter. Amundi now owns 2,693,664 shares of the company’s stock worth $788,570,000 after purchasing an additional 1,597,497 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in Elevance Health in the 2nd quarter worth $591,084,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Elevance Health

In other news, EVP Ratnakar Lavu sold 1,300 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the sale, the executive vice president directly owned 14,849 shares in the company, valued at approximately $6,533,560. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the sale, the chief financial officer directly owned 19,919 shares in the company, valued at $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.34% of the stock is currently owned by insiders.

Elevance Health Stock Up 0.1%

Shares of Elevance Health stock opened at $426.17 on Monday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $450.69. The company’s 50 day moving average price is $412.92 and its 200-day moving average price is $373.58. The stock has a market capitalization of $92.08 billion, a price-to-earnings ratio of 18.17, a P/E/G ratio of 2.03 and a beta of 0.63.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. During the same period in the prior year, the business posted $6.03 EPS. The firm’s revenue was up .7% compared to the same quarter last year. Equities research analysts forecast that Elevance Health, Inc. will post 29.15 EPS for the current year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. Elevance Health’s payout ratio is presently 29.34%.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. TD Cowen boosted their price target on shares of Elevance Health from $465.00 to $495.00 and gave the stock a “buy” rating in a research note on Friday, October 23rd. Guggenheim raised their price objective on Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Robert W. Baird lifted their price objective on Elevance Health from $393.00 to $406.00 and gave the stock a “neutral” rating in a report on Thursday, October 22nd. Royal Bank Of Canada boosted their target price on Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research note on Thursday, October 22nd. Finally, UBS Group increased their target price on Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a report on Thursday, October 22nd. Fifteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $456.48.

Elevance Health Profile

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.